Collegium Pharmaceutical (COLL) EBIT Growth (3y) (2017 - 2026)
Collegium Pharmaceutical (COLL) EBIT Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 29.31% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 4.24% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 0.90% |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 1.82% |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | -74.25% |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 27.21% |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 35.42% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Collegium Pharmaceutical | 892.02 Mn | 742.71 Mn | 110.29 Mn | -53.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.01% |
| Mar 31, 2026 | 7.85% |
| Dec 31, 2025 | 72.89% |
| Sep 30, 2025 | 44.76% |
| Jun 30, 2025 | 46.74% |
| Mar 31, 2025 | 60.90% |
| Dec 31, 2024 | 46.07% |
| Sep 30, 2024 | 35.04% |
| Jun 30, 2024 | 42.49% |
| Mar 31, 2024 | 32.66% |
| Dec 31, 2023 | 60.23% |
| Sep 30, 2023 | 31.88% |
| Jun 30, 2023 | 29.13% |
| Mar 31, 2023 | 69.46% |
| Dec 31, 2022 | 90.88% |
| Sep 30, 2022 | 73.36% |
| Jun 30, 2022 | 61.58% |
| Mar 31, 2022 | -0.08% |
| Dec 31, 2021 | -72.15% |
| Sep 30, 2021 | 48.35% |